Overview
ISO/TS 16550:2014 (Nanotechnologies) specifies a laboratory test method to evaluate the potency of silver nanoparticles (AgNPs) by measuring release of muramic acid (MA) from the cell wall of Staphylococcus aureus. The method uses sample preparation, hydrolysis and derivatization of bacterial cell wall material and quantifies muramic acid by gas chromatography–mass spectrometry (GC‑MS) as an indirect indicator of AgNP-induced peptidoglycan degradation.
Key topics and technical requirements
- Principle: AgNPs can damage bacterial peptidoglycan, releasing MA. Monitoring MA concentration is an indirect, sensitive measure of cell‑wall degradation (does not by itself indicate lethality).
- Test organism and culture: S. aureus ATCC 25923 grown to mid‑log phase (OD600 ≈ 0.45–0.50; ~1–2 × 10^9 CFU/ml recommended) and incubated with AgNPs.
- Exposure conditions: Incubation typically 18 h at 37 °C with shaking (180–200 rpm). At least five treatment concentrations are recommended to establish a dose–response.
- Sample preparation: Clarification by centrifugation and filtration, drying (rotary evaporator and freeze drier), followed by hydrolysis and derivatization prior to GC‑MS analysis.
- Analytical method: GC‑MS instrumentation (Annex A) with use of an internal standard (Annex B). The specification discusses limit of detection (LOD), limit of quantification (LOQ), linear dynamic range and data interpretation.
- Quality and validation: Use of a laboratory‑prepared AgNP calibration/system validation reference material (Annex C), recommended controls (positive, negative, bacterial suitability in Annex E), and guidance on AgNP suspension prep (Annex D).
- Characterization context: The document notes AgNP activity depends on size, shape, surface chemistry and dissolution; the MA assay measures one mode of action (cell‑wall degradation) and is not a comprehensive bactericidal assessment.
Applications and users
ISO/TS 16550:2014 is useful for:
- Manufacturers and R&D teams developing antibacterial silver nanoparticle formulations (medical coatings, textiles, wound care).
- Analytical and microbiology laboratories performing potency testing or product benchmarking of AgNPs.
- Regulatory and safety scientists assessing nanomaterial biological activity and environmental/health risk screening.
- Quality control groups establishing batch‑to‑batch consistency for AgNP‑containing products.
The standard supports reproducible, sensitive measurement of a targeted biological effect and can inform formulation optimization and safety assessment workflows.
Related standards and terms
- References and related ISO documents cited in the specification include ISO 20752, ISO/TS 15216‑1, ISO/TS 10797, ISO/TS 80004‑6, and general ISO/TC 229 (Nanotechnologies) guidance.
- Key keywords: ISO/TS 16550:2014, silver nanoparticles, AgNP potency, muramic acid, Staphylococcus aureus, GC‑MS, peptidoglycan, nanotechnologies, antibacterial testing.